The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Clinical Features of Early-Onset Alzheimer Disease in a Large Kindred With an E280A Presenilin-1 Mutation
Abstract
OBJECTIVES: To characterize clinical features of a very large pedigree with early-onset Alzheimer disease (AD) in which all affected individuals carry the identical glutamic acid-to-alanine mutation at codon 280 in the presenilin-1 gene. DESIGN: Clinical histories were obtained by patient and family interviews and through medical or civil records. Using standard diagnostic criteria, a case series of 128 individuals was identified, of which 6 have definitive (autopsy-proven) early-onset AD, 93 have probable early-onset AD, and 29 have possible early-onset AD. SETTING: Community based in Antioquia, Colombia. PATIENTS: A population-based sample in which all members of 5 extended families (nearly 3000 individuals) were surveyed. Criteria for inclusion required obtaining sufficient information to categorize the individual as affected. MAIN OUTCOME MEASURES: Age at onset, neuropsychological profile, neurologic history, and examination. RESULTS: The patients had a mean age at onset of 46.8 years (range, 34-62 years). The average interval until death was 8 years. Headache was noted in affected individuals significantly more frequently than in those not affected. The most frequent presentation was memory loss followed by behavior and personality changes and progressive loss of language ability. In the final stages, gait disturbances, seizures, and myoclonus were frequent. CONCLUSIONS: Other than the early onset, this clinical phenotype is indistinguishable from sporadic AD except that affected individuals frequently complained of headache preceding and during the disease. Despite the uniform genetic basis for the disease, there was significant variability in the age at onset, suggesting an important role for environmental factors or genetic modifiers in determining the age at onset.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Large ADAD families such as the kindred harboring the Colombian PSEN1 NM_000021:c.839A>C,p. (Glu280Ala) (canonically known as PSEN1 E280A) mutation, the world's largest ADAD founder population with a comprehensive family tree of thousands of individuals [3], provide an opportunity to assess the contribution of genetic variation to unexplained variability in age of dementia onset.”
From Genetic associations with age at dementia onset in the PSEN1 E280A Colombian kindred (2023) · cites this paper as [3]
In the citing paper
“This study addresses these limitations by employing a well-described phenotype in a geographically isolated population with a monogenic form of AD [3].”
From Genetic associations with age at dementia onset in the PSEN1 E280A Colombian kindred (2023) · cites this paper as [3]
In the citing paper
“For the past three decades, we have studied the world's largest known pedigree in which a presenilin-1 (PSEN1) mutation (p.Glu280Ala, E280A), often referred as the Paisa mutation, dominantly cosegregates with early-onset of Alzheimer's disease (AD).1”
From APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease (2016) · cites this paper as [1]
In the citing paper
“Our present study mitigates most of these confounders by using an expertly phenotyped, geographically isolated founder population affected with a monogenic early-onset form of AD.8”
From Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer's disease (2015) · cites this paper as [8]
In the citing paper
“The age at clinical onset of autosomal dominant Alzheimer’s disease is similar between generations14 and is affected mostly by the mutation type and background family genetics.15”
From Clinical and biomarker changes in dominantly inherited Alzheimer's disease (2012) · cites this paper as [14]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Kaplan, E., Goodglass, H., Weıntraub, S., & Segal, O. (2001) · Medical Entomology and Zoology · Cited by 4,378
(1998) · Cited by 4,172
Moms, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D., & Clark, C. (1989) · Neurology · doi:10.1212/wnl.39.9.1159 · Cited by 4,130
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
The Halstead-Reitan neuropsychological test battery: Theory and clinical interpretation
Reitan, R. M., & Wolfson, D. E. (1993) · Medical Entomology and Zoology · Cited by 3,413
Cited by
Sorted by citations
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676
Kalaria, R. N., Maestre, G. E., Arizaga, R., Friedland, R. P., Galasko, D., Hall, K., Luchsinger, J. A., Ogunniyi, A., Perry, E. K., Potocnik, F., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70169-8 · Cited by 1,233
Does neuroinflammation fan the flame in neurodegenerative diseases?
Frank-Cannon, T. C., Alto, L. T., McAlpine, F. E., & Tansey, M. G. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-47 · Cited by 751
Imaging the evolution and pathophysiology of Alzheimer disease
Jagust, W. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0067-3 · Cited by 604
Reiman, E. M., Quiroz, Y. T., Fleisher, A. S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., Fagan, A. M., Shah, A. R., Alvarez, S., Arbelaez, A., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70228-4 · Cited by 541
Self-citationSymptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis
Ryman, D. C., Acosta-Baena, N., Aisen, P. S., Bird, T., Danek, A., Fox, N. C., Goate, A., Frommelt, P., Ghetti, B., Langbaum, J. B. S., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000596 · Cited by 502
Self-citationLongitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease
Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434
Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments
Reiman, E. M., Langbaum, J. B. S., Fleisher, A., Caselli, R. J., Chen, K., Ayutyanont, N., Quiroz, Y. T., Kosik, K. S., Lopera, F. J., & Tariot, P. N. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-0059 · Cited by 340
Self-citationVisual short-term memory binding deficits in familial Alzheimer’s disease
Parra, M. A., Abrahams, S., Logie, R. H., Méndez, L., Lopera, F. J., & Sala, S. D. (2010) · Brain · doi:10.1093/brain/awq148 · Cited by 328
Self-citationCarvajal‐Carmona, L. G., Soto‐Calderón, I. D., Pineda-Trujillo, N., Ortíz-Barrientos, D., Duque, C., Ospina-Duque, J., McCarthy, M. I., Montoya, P., Alvarez, V. M., Bedoya, G., et al. (2000) · The American Journal of Human Genetics · doi:10.1016/s0002-9297(07)62956-5 · Cited by 310
Recognition of the amyloid precursor protein by human γ-secretase
Zhou, R., Yang, G., Guo, X., Zhou, Q., Lei, J., & Shi, Y. (2019) · Science · doi:10.1126/science.aaw0930 · Cited by 304
Genetics of population isolates
Arcos‐Burgos, M., & Muenke, M. (2002) · Clinical Genetics · doi:10.1034/j.1399-0004.2002.610401.x · Cited by 271
McAlpine, F. E., Lee, J., Harms, A. S., Ruhn, K. A., Blurton-Jones, M. M., Hong, J. J., Das, P., Golde, T. E., LaFerla, F. M., Oddo, S., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.01.006 · Cited by 274
Acosta-Baena, N., Sepulveda-Falla, D., Lopera-Gómez, C. M., Jaramillo-Elorza, M. C., Moreno, S., Aguirre-Acevedo, D. C., Saldarriaga, A., & Lopera, F. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70323-9 · Cited by 263
Self-citationLarner, A. J., & Doran, M. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0019-5 · Cited by 264
Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease
Quiroz, Y. T., Budson, A. E., Celone, K., Ruiz‐Rizzo, A. L., Newmark, R. E., Castrillón, G., Lopera, F. J., & Stern, C. E. (2010) · Annals of Neurology · doi:10.1002/ana.22105 · Cited by 261
Self-citationFleisher, A., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gomez, M. G., Langois, C. M., Langbaum, J. B. S., Ayutyanont, N., Roontiva, A., Thiyyagura, P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70227-2 · Cited by 246
Self-citationSeizures in Elderly Patients with Dementia
Mendez, M. F., & Lim, G. T. H. (2003) · Drugs & Aging · doi:10.2165/00002512-200320110-00001 · Cited by 219
Early-Onset Familial Alzheimer's Disease (EOFAD)
Wu, L., Rosa‐Neto, P., Hsiung, G. R., Sadovnick, A. D., Masellis, M., Black, S. E., Jia, J., & Gauthier, S. G. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013949 · Cited by 240
Immunotherapy for Alzheimer’s disease: hoops and hurdles
Lemere, C. A. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-36 · Cited by 196
Apolipoprotein Eε4 modifies Alzheimer's disease onset in an E280A PS1 kindred
Pastor, P., Roe, C. M., Villegas, A., Bedoya, G., Chakraverty, S., García, G., Tirado, V., Norton, J., Ríos, S., Martínez, M., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10636 · Cited by 194
Self-citationPathway-driven discovery of epilepsy genes
Noebels, J. L. (2015) · Nature Neuroscience · doi:10.1038/nn.3933 · Cited by 191
Quiroz, Y. T., Sperling, R. A., Norton, D. J., Baena, A., Arboleda-Velasquez, J. F., Cosio, D., Schultz, A., Lapoint, M., Guzman-Velez, E., Miller, J. B., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4907 · Cited by 186
Self-citationRecognition of the Amyloid Precursor Protein by Human gamma-secretase
Zhou, R., Yang, G., Guo, X., Zhou, Q., Lei, J., & Shi, Y. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6iyc/pdb · Cited by 189
Bature, F., Guinn, B., Pang, D., & Pappas, Y. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015746 · Cited by 201
A global view of the genetic basis of Alzheimer disease
Reitz, C., Pericak‐Vance, M. A., Foroud, T., & Mayeux, R. P. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00789-z · Cited by 181
More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration
Lane-Donovan, C., Philips, G. T., & Herz, J. (2014) · Neuron · doi:10.1016/j.neuron.2014.08.005 · Cited by 158
Short-term memory binding is impaired in AD but not in non-AD dementias
Sala, S. D., Parra, M. A., Fabi, K., Luzzi, S., & Abrahams, S. (2012) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2012.01.018 · Cited by 142
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials
Moulder, K. L., Snider, B., Mills, S. L., Buckles, V. D., Santacruz, A. M., Bateman, R. J., & Morris, J. C. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt213 · Cited by 142
Shea, Y. F., Chu, L., Chan, A. O.-K., Ha, J. C. T., Li, Y., & Song, Y. (2015) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2015.08.004 · Cited by 148
Sepulveda-Falla, D., Barrera-Ocampo, A., Hagel, C., Korwitz, A., Vinueza-Veloz, M. F., Zhou, K., Schonewille, M., Zhou, H., Velazquez-Perez, L., Rodriguez-Labrada, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66407 · Cited by 135
Self-citationSiman, R., Reaume, A. G., Savage, M. J., Trusko, S., Lin, Y.-G., Scott, R. W., & Flood, D. G. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-23-08717.2000 · Cited by 133
Gómez‐Isla, T., Growdon, W. B., McNamara, M. J., Nochlin, D., Bird, T. D., Arango, J. C., Lopera, F., Kosik, K. S., Lantos, P. L., Cairns, N. J., et al. (1999) · Brain · doi:10.1093/brain/122.9.1709 · Cited by 131
Self-citationTariot, P. N., Lopera, F., Langbaum, J. B., Thomas, R. G., Hendrix, S., Schneider, L. S., Rios‐Romenets, S., Giraldo, M., Acosta, N., Tobon, C., et al. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.02.002 · Cited by 128
Self-citationCan we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease
Carrillo, M. C., Brashear, H. R., Logovinsky, V., Ryan, J. M., Feldman, H., Siemers, E., Abushakra, S. R., Hartley, D. M., Petersen, R. C., Khachaturian, A. S., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.12.004 · Cited by 128
Genetic diagnosis and prognosis of Alzheimer’s disease: challenges and opportunities
Reitz, C. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1002469 · Cited by 125
Quiroz, Y. T., Schultz, A. P., Chen, K., Protas, H. D., Brickhouse, M. J., Fleisher, A., Langbaum, J. B. S., Thiyyagura, P., Fagan, A. M., Shah, A. R., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1099 · Cited by 124
Self-citationArdila, A., Lopera, F., Rosselli, M., Moreno, S., Madrigal, L., Arango-Lasprilla, J. C., Arcos, M., Murcia, C., Arango-Viana, J. C., Ossa, J., et al. (2000) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/15.6.515 · Cited by 113
Self-citationAPOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease
Vélez, J. I., Lopera, F., Sepulveda-Falla, D., Patel, H. R., Johar, A. S., Chuah, A., Tobón, C., Rivera, D., Villegas, A., Cai, Y., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.177 · Cited by 111
Self-citationPerformance of Some Estimators of Relative Variability
Ospina, R., & Marmolejo‐Ramos, F. (2019) · Frontiers in Applied Mathematics and Statistics · doi:10.3389/fams.2019.00043 · Cited by 113
Caselli, R. J., & Reiman, E. M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129026 · Cited by 111
Biomarkers in Sporadic and Familial Alzheimer’s Disease
Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143006 · Cited by 106
Parra, M. A., Sala, S. D., Abrahams, S., Logie, R. H., Méndez, L., & Lopera, F. J. (2011) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2011.03.022 · Cited by 112
Self-citationAge at onset in genetic prion disease and the design of preventive clinical trials
Minikel, E. V., Vallabh, S. M., Orseth, M. C., Brandel, J., Haı̈k, S., Laplanche, J., Zerr, I., Parchi, P., Capellari, S., Safar, J., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007745 · Cited by 104
Additive Effects of PS1 and APP Mutations on Secretion of the 42-Residue Amyloid β-Protein
Citron, M., Eckman, C. B., Diehl, T. S., Corcoran, C., Ostaszewski, B. L., Xia, W., Levesque, G., St. George Hyslop, P., Younkin, S. G., & Selkoe, D. J. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0183 · Cited by 101
Li, X., Guo, F., Zhang, Q., Huo, T., Liu, L., Wei, H., Xiong, L., & Wang, Q. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-37 · Cited by 102
Panza, F., Solfrizzi, V., Imbimbo, B. P., Tortelli, R., Santamato, A., & Logroscino, G. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.883921 · Cited by 103
Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
Panza, F., Logroscino, G., Imbimbo, B. P., & Solfrizzi, V. (2014) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000041 · Cited by 101
Kalaria, R. N., Maestre, G. E., Mahinrad, S., Acosta, D. M., Akinyemi, R., Alladi, S., Allegri, R., Arshad, F., Babalola, D. O., Baiyewu, O., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13836 · Cited by 110
TEC Monitoring by Using Satellite Positioning Systems
Jakowski, N. (1996) · elib (German Aerospace Center) · Cited by 97
Variant Alzheimer’s disease with spastic paraparesis
Verkkoniemi, A., Somer, M., Rinne, J. O., Myllykangas, L., Crook, R., Hardy, J., Viitanen, M. H., Kalimo, H., & Haltia, M. (2000) · Neurology · doi:10.1212/wnl.54.5.1103 · Cited by 96
Arcos‐Burgos, M., Parodi, E., Salgar, M., Bedoya, E., Builes, J. J., J., D. E. J., Gabriel Ceballos, C., Uribe, A., Rivera, N., Rivera, D., et al. (2002) · Human Genetics · doi:10.1007/s00439-002-0687-5 · Cited by 94
Duarte, A. I., Candeias, E., Alves, I. N., Mena, D., da Silva, D. F., Machado, N. J., Campos, E. J., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051746 · Cited by 94
Clinical, Pathological, and Biochemical Spectrum of Alzheimer Disease Associated With PS-1 Mutations
Lleó, A., Berezovska, O., Growdon, J. H., & Hyman, B. T. (2004) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200403000-00006 · Cited by 94
Apolipoprotein E in Alzheimer’s disease: molecular insights and therapeutic opportunities
Belaidi, A. A., Bush, A. I., & Ayton, S. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00843-y · Cited by 91
Aluminum and Amyloid-β in Familial Alzheimer’s Disease
Mold, M. J., Linhart, C., Gómez‐Ramirez, J., Villegas‐Lanau, A., & Exley, C. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191140 · Cited by 86
Lehman, E. J. H. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg322 · Cited by 85
Variant Alzheimer Disease With Spastic paraparesis: Neuropathological phenotype
Verkkoniemi, A., Kalimo, H., Paetau, A. E., Somer, M., Iwatsubo, T., Hardy, J., & Haltia, M. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.5.483 · Cited by 85
Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities
O’Riordan, S., McMonagle, P., Janssen, J. C., Fox, N. C., Farrell, M., Collinge, J., Rossor, M. N., & Hutchinson, M. (2002) · Neurology · doi:10.1212/wnl.59.7.1108 · Cited by 83
van Etten, E. S., Verbeek, M. M., van der Grond, J., Zielman, R., van Rooden, S., van Zwet, E. W., van Opstal, A. M., Haan, J., Greenberg, S. M., van Buchem, M. A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003486 · Cited by 84
Deposition of Hyperphosphorylated Tau in Cerebellum of PS1 E280A Alzheimer's Disease
Sepulveda‐Falla, D., Matschke, J., Bernreuther, C., Hagel, C., Puig, B., Villegas, A., Garcia, G., Zea, J., Gomez‐Mancilla, B., Ferrer, I., et al. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00469.x · Cited by 82
Self-citationTakao, M., Ghetti, B. F., Hayakawa, I., Ikeda, E., Fukuuchi, Y., Miravalle, L., Piccardo, P., Murrell, J. R., Glazier, B. S., & Koto, A. (2002) · Acta Neuropathologica · doi:10.1007/s00401-002-0536-6 · Cited by 81
Ospina-Duque, J., Duque, C., Carvajal‐Carmona, L. G., Ortíz-Barrientos, D., Soto‐Calderón, I. D., Pineda-Trujillo, N., Arias, J. M. C., Calle, J., López‐Jaramillo, C., Ochoa, L., et al. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01464-6 · Cited by 81
Memory binding and white matter integrity in familial Alzheimer’s disease
Parra, M. A., Saarimäki, H., Bastin, M. E., Londoño, A. C., Pettit, L., Lopera, F., Della Sala, S., & Abrahams, S. (2015) · Brain · doi:10.1093/brain/awv048 · Cited by 79
Self-citationAPOE and other loci affect age‐at‐onset in Alzheimer's disease families with PS2 mutation
Wijsman, E. M., Daw, E. W., Yu, X., Steinbart, E. J., Nochlin, D., Bird, T. D., & Schellenberg, G. D. (2005) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30087 · Cited by 79
The Alzheimer’s Prevention Initiative Composite Cognitive Test Score
Ayutyanont, N., Langbaum, J. B. S., Hendrix, S. B., Chen, K., Fleisher, A., Friesenhahn, M. J., Ward, M. E., Aguirre, C., Acosta‐Baena, N., Madrigal, L., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08927 · Cited by 84
Self-citationLalli, M. A., Bettcher, B. M., Arcila, M. L., Garcia, G., Guzman, C., Madrigal, L., Ramirez, L., Acosta-Uribe, J., Baena, A., Wojta, K. J., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.131 · Cited by 73
Self-citationStorandt, M., Balota, D. A., Aschenbrenner, A. J., & Morris, J. C. (2013) · Neuropsychology · doi:10.1037/neu0000030 · Cited by 79
Panza, F., Solfrizzi, V., Imbimbo, B. P., & Logroscino, G. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.935332 · Cited by 80
Phenotypic Profile of Early-Onset Familial Alzheimer's Disease Caused by Presenilin-1 E280A Mutation
Sepulveda-Falla, D., Glatzel, M., & Lopera, F. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120907 · Cited by 75
Self-citationPresenilin-1–associated abnormalities in regional cerebral perfusion
Johnson, K. A., Lopera, F. J., Jones, K., Becker, A., Sperling, R. A., Hilson, J., Londono, J., Siegert, I., Arcos‐Burgos, M., Moreno, S., et al. (2001) · Neurology · doi:10.1212/wnl.56.11.1545 · Cited by 76
Self-citationNongenetic Factors as Modifiers of the Age of Onset of Familial Alzheimer’s Disease
Mejía-Arango, S., Giraldo, M., Pineda, D. A., Lopera, F. J., & Ardila, A. (2003) · International Psychogeriatrics · doi:10.1017/s1041610203009591 · Cited by 73
Self-citationRygiel, K. (2016) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.194867 · Cited by 76
Presymptomatic cortical thinning in familial Alzheimer disease
Weston, P. S. J., Nicholas, J. M., Lehmann, M., Ryan, N. S., Liang, Y., Macpherson, K., Marc Modat, A., Rossor, M. N., Schott, J. M., Sebastien Ourselin, A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003322 · Cited by 71
Mak, E., Gabel, S., Mirette, H., Su, L., Williams, G. B., Waldman, A., Wells, K., Ritchie, K., Ritchie, C., & O’Brien, J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.10.001 · Cited by 71
Morris, J. C., Weiner, M., Xiong, C., Beckett, L., Coble, D., Saito, N., Aisen, P. S., Allegri, R., Benzinger, T. L. S., Berman, S. B., et al. (2022) · Brain · doi:10.1093/brain/awac181 · Cited by 68
Velez‐Pardo, C., Arellano, J. I., Cardona‐Gómez, G. P., Jiménez-Del-Río, M., Lopera, F. J., & DeFelipe, J. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.55403.x · Cited by 72
Self-citationMolecular genetics of Alzheimer’s disease
Pástor, P., & Goate, A. (2004) · Current Psychiatry Reports · doi:10.1007/s11920-004-0052-6 · Cited by 69
Lowe, J. S., Mirra, S. S., Hyman, B. T., & Dickson, D. W. (2008) · CRC Press eBooks · doi:10.1201/b13319-15 · Cited by 68
Arcos‐Burgos, M., Castellanos, F. X., Konecki, D. S., Lopera, F. J., Pineda, D. A., Palacio, J. D., Rapoport, J. L., Berg, K., Wilson, J., & Muenke, M. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001396 · Cited by 67
Self-citationFeature Binding Deficits in Subjective Cognitive Decline and in Mild Cognitive Impairment
Koppara, A., Frommann, I., Polcher, A. A., Parra, M. A., Maier, W., Jessen, F., Klockgether, T., & Wagner, M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150105 · Cited by 66
Pietto, M. L., Parra, M. A., Trujillo, N., Flores, F., García, A. M., Bustin, J., Richly, P., Manes, F. F., Lopera, F. J., Ibáñez, A. M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160056 · Cited by 66
Self-citationDiagnostic Validity of the Dementia Questionnaire for Alzheimer Disease
Ellis, R. J., Jan, K., Kawas, C. H., Koller, W. C., Lyons, K. E., Jeste, D. V., Hansen, L. A., & Thal, L. J. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.360 · Cited by 66
The Bad, the Good, and the Ugly about Oxidative Stress
Jiménez-Del-Río, M., & Velez‐Pardo, C. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/163913 · Cited by 65
Leko, M. B., Horvat, L. L., Španić, E., Zubčić, K., Hof, P. R., & Šimić, G. (2023) · Biomedicines · doi:10.3390/biomedicines11041161 · Cited by 64
Amyloid-beta immunotherapy: the hope for Alzheimer disease?
Barrera-Ocampo, A. A., & Lopera, F. J. (2016) · Colombia medica · doi:10.25100/cm.v47i4.2640 · Cited by 64
Self-citationAPOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease
Quiroz, Y. T., Aguillon, D., Aguirre-Acevedo, D. C., Vasquez, D., Zuluaga, Y., Baena, A. Y., Madrigal, L., Hincapié, L., Sanchez, J. S., Langella, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2308583 · Cited by 63
Self-citationExecutive functions in clinical and preclinical Alzheimer's disease
Allain, P., Etcharry‐Bouyx, F., & Verny, C. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.020 · Cited by 74
Lista, S., Dubois, B., & Hampel, H. J. (2014) · The journal of nutrition health & aging · doi:10.1007/s12603-014-0515-3 · Cited by 61
Origin of the PSEN1 E280A mutation causing early‐onset Alzheimer's disease
Lalli, M. A., Cox, H. C., Arcila, M. L., Cadavid, L., Moreno, S., Garcia, G., Madrigal, L., Reiman, E. M., Arcos‐Burgos, M., Bedoya, G., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.09.005 · Cited by 60
Self-citationFuller, J. T., Cronin-Golomb, A., Gatchel, J. R., Norton, D. J., Guzmán-Vélez, E., Jacobs, H. I. L., Hanseeuw, B., Pardilla-Delgado, E., Artola, A., Baena, A., et al. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.6 · Cited by 57
Self-citationArango, D., Cruts, M., Torres, O., Backhovens, H., Serrano, M. L., Villareal, E., Monta�es, P., Matallana, D., Cano, C. A., Broeckhoven, C. V., et al. (2001) · American Journal of Medical Genetics · doi:10.1002/1096-8628(20011001)103:2 · Cited by 59
Pineda-Trujillo, N., Carvajal‐Carmona, L. G., Buriticá, O., Moreno, S., Uribe, C. S., Pineda, D. A., Toro, M. F., Garcı́a, F., Arias, W. H., Bedoya, G., et al. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01733-x · Cited by 58
Self-citationKarve, S. J., Ringman, J. M., Lee, A. S., Juarez, K. O., & Mendez, M. F. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6481-y · Cited by 63
Aguillon, D., Langella, S., Chen, Y., Sanchez, J. S., Su, Y., Vila‐Castelar, C., Vasquez, D., Zetterberg, H., Hansson, O., Dage, J. L., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12906 · Cited by 54
Self-citationGenetic Phenotypes of Alzheimer’s Disease: Mechanisms and Potential Therapy
Quan, M., Cao, S., Wang, Q., Wang, S., & Jia, J. (2023) · Phenomics · doi:10.1007/s43657-023-00098-x · Cited by 62
Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer’s disease
Tansey, M. G., & McAlpine (2008) · Journal of Inflammation Research · doi:10.2147/jir.s4397 · Cited by 55
Alzheimer’s disease and related tauopathies: disorders of disrupted neuronal identity
Frost, B. E. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.07.006 · Cited by 57
Metadata
- Authors
- Lopera, F.
- Affiliations
- Universidad de Antioquia (CO)
- Corresponding author
- Lopera, Francisco
- ORCID
- Lopera, Francisco
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 1997-03-12
- Volume
- 277
- Issue
- 10
- Pages
- 793
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2110985141
- Cited by
- 351
- References
- 52
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 19 · 2023: 17 · 2022: 8 · 2021: 14 · 2020: 16 · 2019: 16 · 2018: 13 · 2017: 13 · 2016: 19 · 2015: 22 · 2014: 21 · 2013: 14 · 2012: 23
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- early-onset Alzheimer's disease, presenilin 1, PSEN1 E280A mutation, familial Alzheimer's disease, clinical phenotype, age of onset, headache, memory loss, behavioral and personality changes, language loss, gait disturbance, seizures, myoclonus, genetic modifiers, extended family
- MeSH terms
- Adult, Alanine, Alzheimer Disease, Autopsy, Brain, Codon, Female, Headache, Humans, Male, Membrane Proteins, Middle Aged, Neuropsychological Tests, Pedigree, Phenotype, Point Mutation, Age of Onset, Glutamic Acid, Presenilin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
